BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

...“It is happening at such a rapid pace...
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

KSQ Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive, global rights to develop, manufacture and commercialize cell and non-cell therapies that modulate targets identified with KSQ's CRISPRomics platform. The deal includes up to...
BioCentury | Jan 13, 2021
Product Development

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...
BioCentury | Jan 11, 2021
Politics, Policy & Law

The U.S. needs a COVID commission: Editor’s Commentary

...The bumbling rollout of mAbs and lackluster pace...
BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

Myriad’s autoimmune unit on the blockMyriad Genetics Inc. (NASDAQ:MYGN) said it will focus on women’s health, cancer and mental health and pursue strategic alternatives for its autoimmune unit. In November on its earnings call, the...
BioCentury | Jan 5, 2021
Product Development

Crucible of COVID, ahoy 2021 & cancer deal trends: a BioCentury podcast

...specialists expect industry to continue its torrid pace...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...has “looked at” some deals larger than $100 million. He said R-Bridge anticipates an investment pace...
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...and Hong Kong IPOs maintaining their steady pace...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...non-viral particle-derived approach could be done at pace...
BioCentury | Dec 31, 2020
Politics, Policy & Law

Innovations forged in the COVID crucible will reshape medicine

...journals to act as gatekeepers, throttling the pace...
...not be possible to maintain the 24/7 pace...
Items per page:
1 - 10 of 1176